This study is being done to see if losing weight may help prevent breast cancer from coming back (recurring).

The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer.

This registry/tissue bank is focused on the collection of detailed information and biological samples on participants to help create a resource that will be helpful to researchers in future studies related to breast cancer.

The purpose of this study is to compare getting more treatment with capecitabine (i.e. one of the usual approaches), to any good and bad effects of getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin), after surgery for patients with triple-negative breast cancer.

The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.

The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery.

This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair.

The purpose of this study is to compare any good and bad effects patients with early stage non-small cell lung cancer that was surgically removed may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

The purpose of this research study is to look at lung cancer patients’ tumors that were removed by surgery for certain genetic changes, and to possibly offer these patients a treatment study with drugs that may specifically target tumors that have these genetic changes.

The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for patients with ALK-positive non-small cell lung cancer.